에 대한 최신 뉴스 Evolent Health (NYSE:EVH) 주식

Evolent Health

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

새로이 등장한 블록 스타벅스(NASDAQ:SBUX)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 경제적 및 경쟁적 압박에 적응하기 위한 파트너십을 모색하고 있다.

딜 디스패치: 스타벅스 중국 사업 매각 고려, 노스볼트 파산, 다윈 파이낸셜이 광업에 대해 논의

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

새로 등장한 블록 에볼런트 헬스(NYSE:EVH)가 매물로 나온 것으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:TPG), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:KKR)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:ELV)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.

딜 디스패치: 쉘, 유니레버 외에도 매각 뉴스; 어니언이 알렉스 존스의 인포워스 인수 등

Asia

Mid Cap

News

Movers

ASTS

IOVA

LUMN

PSNY

SFTBF

SMTC

UPST

이들 10개의 중형주는 8월에 가장 좋은 성과를 보였다. 이 주식들이 귀하의 포트폴리오에 포함되어 있나요? 1. 폴스타 오토모티브 홀딩(NASDAQ:PSNY)의 주식이 8월에 74.19% 급등했다. 이는 2분기 강력한 인도량을 발표한 후 발생한 일이다.

AST 스페이스모바일 및 폴스타는 8월에 최고 성과를 보여준 10개 중형주 중 일부

Evolent Health Inc

EVENT HOSPITALITY & ENTMT by EVENT HOSPITALITY & ENTMT LTD.

EVT Ltd

Morgan Stanley ETF Trust Eaton Vance High Yield ETF

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and lowers the price target from $15 to $13.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $13

Oppenheimer analyst Jeff Jones maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Outperform and lowers the price target from $28 to $18.

Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $18

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $23 to $16.

Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $16

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $20 to $15.

Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $15

Stephens &amp; Co. analyst Jeff Garro maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Equal-Weight and lowers the price target from $16 to $12.

Stephens & Co. Maintains Equal-Weight on Evolent Health, Lowers Price Target to $12

UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $27 to $14.

UBS Maintains Buy on Evolent Health, Lowers Price Target to $14

Needham analyst Ryan MacDonald reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $15 price target.

Reiteration

Needham Reiterates Buy on Evolent Health, Maintains $15 Price Target

13 analysts have shared their evaluations of Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Evolent Health and provided 12-month price targets. The average target is $21.08, accompanied by a high estimate of $34.00 and a low estimate of $15.00. A decline of 32.39% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1736884839_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Evolent Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Evolent Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Evolent Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Evolent Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Evolent Health showcased positive performance, achieving a revenue growth rate of 21.6% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Evolent Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.03% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Evolent Health's ROE stands out, surpassing industry averages. With an impressive ROE of -2.99%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evolent Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.61, Evolent Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Evolent Health Stock

WIIM

Evolent Health shares are trading lower after RBC Capital cut its price target on the stock from $20 to $17.

RBC Capital analyst Sean Dodge maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Outperform and lowers the price target from $20 to $17.

RBC Capital Maintains Outperform on Evolent Health, Lowers Price Target to $17

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $24 to $20.

Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $20

Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $21 to $18.

Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $18

JMP Securities analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and lowers the price target from $27 to $18.

JMP Securities Maintains Market Outperform on Evolent Health, Lowers Price Target to $18

Needham analyst Matthew Sheerin initiates coverage on Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy rating and announces Price Target of $15.

Initiation

Needham Initiates Coverage On Evolent Health with Buy Rating, Announces Price Target of $15

<h3 class="wp-block-heading">New On The Block</h3>
<ul>
<li>Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is looking to sell a stake in its Chinese operations. Same-store sales in China fell 14% last quarter, with the Seattle-based coffee retailer seeking partnerships to adapt to tough <a href="https://www.benzinga.com/news/asset-sales/24/11/42117962/starbucks-eyes-stake-sale-in-china-amid-fierce-competition-and-falling-sales">economic and competitive pressures</a>.</li>
</ul>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
<ul>
<li>Snack producer Hearthside Food Solutions went bankrupt. The private equity-owned company looks to offload the $1.9 billion in debt accumulated under the ownership of Partners Group Holding AG and Charlesbank Capital Partners. The two firms bought Hearthside for more than $2.4 billion. Assets and liabilities hover between $1 billion and $10 billion. Last year, bankrupt private equity portfolio companies in the U.S. <a href="https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/private-equity-portfolio-companies-on-track-for-most-bankruptcies-since-2020-74886821">outpaced</a> the number of <a href="https://www.benzinga.com/news/20/10/17861269/bankruptcy-update-ruby-tuesday-files-chapter-11-while-progress-slows-for-jcpenney">bankruptcies in 2020</a>. It remains to be seen whether 2024 will be worse.</li>
</ul>
<ul>
<li>Northvolt <a href="https://northvolt.com/articles/peter-carlsson-steps-aside/">filed</a> for bankruptcy with debt of $5.8 billion. Recall how the Swedish battery maker, which supplies Volkswagen AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) and&nbsp;Bayerische Motoren Werke AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMWYY#OTC">BMWYY</a>), bargained with banks to <a href="https://www.benzinga.com/news/23/03/31506581/volkswagen-bmw-battery-supplier-northvolt-eyes-raising-5b-via-debt">raise debt last year</a>. Now, it&#8217;s hoping to restructure under U.S. Chapter 11.</li>
</ul>
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42024210/benzinga-bulls-and-bears-tesla-disney-gold-and-hedge-funds-project-bitcoin-to-hit-100k-150k">Benzinga Bulls And Bears: Tesla, Disney, Gold — And Hedge Funds Project Bitcoin To Hit $100K-$150K</a>
<h3 class="wp-block-heading">Updates From The Block</h3>
<ul>
<li>Google&#8216;s $2-billion <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">investment</a> in Anthropic is in jeopardy, according to <a href="https://www.bloomberg.com/news/articles/2024-11-21/us-justice-department-seeks-to-unwind-google-s-anthropic-deal">Bloomberg</a>. Anthropic is a Jeff Bezos-backed rival to artificial intelligence (AI) innovator OpenAI. The U.S. Department of Justice (DOJ) recommended in <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">a court filing Wednesday</a> that Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google divest its Chrome browser to dismantle its monopoly on online search. It doesn&#8217;t end there. Google should be barred from doing any deals with companies that control where consumers search for information, regulators say. <a href="https://www.benzinga.com/tech/24/11/42123646/google-anthropic-deal-in-jeopardy-as-us-justice-department-looks-to-snap-online-search-monopoly">That includes AI products</a>.</li>
</ul>
<ul>
<li>Ricky Williams&#8216; Highsman merges with hemp brand Frozen Fields, forming Top Seed Inc. The partnership blends cannabis and hemp sectors, leveraging R&amp;D to enhance products <a href="https://www.benzinga.com/markets/cannabis/24/11/42097662/ricky-williams-highsman-merges-with-hemp-brand-frozen-fields">and control supply chains</a>.</li>
</ul>
<ul>
<li>MakeMyTrip acquires Happay from CRED. The deal is expected to enhance corporate travel and expense management solutions in India. Happay&#8217;s team will integrate with MakeMyTrip, supporting <a href="https://www.benzinga.com/general/travel/24/11/42039458/makemytrip-agrees-to-acquire-happay-bolstering-its-arsenal-for-corporate-travel-solutions">over 900 clients post-acquisition</a>.</li>
</ul>
<ul>
<li>Amcor plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) and Berry Global Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) agreed to merge in an all-stock transaction, with the deal valuing Berry stock <a href="https://www.benzinga.com/news/large-cap/24/11/42069248/amcor-and-berry-seal-the-deal-73-59-per-share-merger-to-forge-packaging-powerhouse">at $73.59 per share</a>.</li>
</ul>
<ul>
<li>Nippon Steel (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NISTF#OTC">NISTF</a>) executives have traveled to Pennsylvania to garner support for their $15 billion acquisition bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>). The Japanese steel giant is encountering political resistance in Washington. Takahiro Mori, vice-chair of Nippon Steel, arrived in Pittsburgh on Saturday to advocate for the acquisition. The deal faces opposition from both President Joe Biden and President-elect Donald Trump, who prefer U.S. Steel to <a href="https://www.benzinga.com/markets/24/11/42056111/nippon-steel-execs-rally-support-in-pennsylvania-amid-pushback-on-us-steel-takeover">remain under American ownership</a>.</li>
</ul>
<h3 class="wp-block-heading">Notes From The Block</h3>
Joshua Robinson, co-founder of Darwin Financial Company, announced a $55-million financing deal with INYOAG LLC. The funds will help develop a solar-powered mine in Inyo County, California where there are proven reserves of silver, lead, zinc, tungsten, and copper. Here&#8217;s our conversation with Robinson:
<h4 class="wp-block-heading">BZ: What is the deal structure between Darwin Financial and base metals miner INYOAG? </h4>
Robinson: The deal structure is a $55M project financing package split into three components: $17.5 million and $12.5 million in six-year notes tied to sulfide and oxide production respectively, plus a $20-million conditional equity commitment that only triggers if the mine hits $10 million in monthly revenue. We get 17% of gross revenues from both production tracks, structured through secure lockbox arrangements. It&#8217;s not a straight equity investment, we specifically designed it this way to provide further upside exposure.
<h4 class="wp-block-heading">Are you looking for additional investors/joint venture partners? </h4>
Yes, we&#8217;ve deliberately structured this to create multiple layers of upside potential, which is pretty unique in the mining space. We&#8217;ve created a hybrid model that offers both near-term cash flow from production and significant expansion potential. We&#8217;re already seeing interest from established mining players, but we&#8217;re particularly excited about bringing new investors into the space who understand the strategic value of critical minerals.
<h4 class="wp-block-heading">What are the downsides to depending on foreign sources of critical minerals?</h4>
China&#8217;s recent actions really highlight the urgency here. They&#8217;ve already implemented export controls on germanium and gallium, and just added antimony to that list. This isn&#8217;t theoretical anymore, it&#8217;s actively happening. We need to build regional resilience in our supply chains, particularly for these minerals that are crucial for defense and technology. The Darwin Mine gives us a unique opportunity to establish a domestic source for multiple critical minerals in a single asset, which is rare to find.
<h4 class="wp-block-heading">Will the mine be powered by solar? </h4>
The 100MW facility wouldn&#8217;t just power the mine. It would generate significant excess clean energy that we can sell back to the grid. What&#8217;s particularly interesting is that we can develop utility-scale energy storage systems using minerals we&#8217;re already producing. It creates a virtuous cycle where our mining operations directly support clean energy deployment
<h4 class="wp-block-heading">What are your 2025 goals?</h4>
For 2025, our key goals are reaching 300 tons per day on sulfide production within six months and 200 tons per day on oxide within nine months of funding. That puts us at $ 10 million in monthly revenue, which then triggers the deeper mine development program.
For last week&#8217;s Deal Dispatch, <a href="https://www.benzinga.com/ma/24/11/42025534/deal-dispatch-shell-unilever-and-more-are-on-the-sell-side-the-onion-makes-alex-jones-cry-foul">click here</a>.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41699259/nvidia-rides-ai-wave-to-replace-intel-on-dow-jones-industrial-average-ending-its-25-year-run">Nvidia Rides AI Wave To Replace Intel On Dow Jones Industrial Average, Ending Its 25-Year Run</a></li>
</ul>
Image: Benzinga

Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and lowers the price target from $45 to $15.

JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $15

Oppenheimer analyst Jeff Jones maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Outperform and lowers the price target from $34 to $28.

Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $28

<h3 class="wp-block-heading">New On The Block</h3>
Evolent Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) is <a href="https://www.benzinga.com/m-a/24/08/40529349/evolent-health-explores-sale-garners-inbound-interest-from-private-equity-firms">reportedly up for sale</a>. The Arlington, Virginia-based software provide initiated an auction process after receiving takeover inquiries. Among the potential suitors are TPG Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), Clayton, Dubilier &amp; Rice, and KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>). Reuters reported that health insurer Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) may join forces with a private equity partner to pursue a deal.
Kronos Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>), a company focused on developing therapies for cancer, is exploring &#8220;strategic alternatives,&#8221; including an acquisition or merger.The San Mateo, Califonia-based company reported $124.9 million in cash reserves as of Sept. 30. 
Saint-Gobain (PARIS:<a class="ticker" href="https://www.benzinga.com/stock/SGO#PARIS">SGO</a>) is considering a sale of its auto glass unit, which could fetch up to 2.5 billion euro ($2.6 billion), per <a href="https://www.bloomberg.com/news/articles/2024-11-13/st-gobain-is-said-to-weigh-2-5-billion-sale-of-auto-glass-unit">Bloomberg</a>. The company is reportedly considering this strategic move as part of its broader business evaluation. This sale aligns with Saint-Gobain&#8217;s efforts to streamline its operations and focus on core business areas.
Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) is seeking to <a href="https://www.bloomberg.com/news/articles/2024-11-13/shell-aims-to-sell-majority-stake-in-carbon-offsets-business?srnd=phx-deals">jettison</a> a majority of its carbon offsets portfolio. The company first launched the portfolio of offsets, which covers dozens of projects, <a href="https://www.bloomberg.com/news/features/2023-08-31/shell-silently-abandoned-its-100-million-a-year-plan-to-offset-co2-emissions" target="_blank" rel="noreferrer noopener">in 2018</a>. 
Unilever (LSE: ULVR) is exploring the sale of some Dutch food brands, including Unox soups and Conimex seasonings. According to Reuters, the company will instead focus on its biggest &#8220;power&#8221; labels.
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42024210/benzinga-bulls-and-bears-tesla-disney-gold-and-hedge-funds-project-bitcoin-to-hit-100k-150k">Benzinga Bulls And Bears: Tesla, Disney, Gold — And Hedge Funds Project Bitcoin To Hit $100K-$150K</a>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
Alex Jones&#8217;s media company, Infowars, is now the property of satirical publication The Onion. The publication&#8217;s backers were none other than the families <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars">of Sandy Hook victims</a>. Observers praised the deal as poetic justice, considering Jones owes over $1 billion in defamation judgments against those families. Jones, who <a href="https://www.benzinga.com/news/23/12/36168941/elon-musks-controversial-move-alex-jones-returns-to-x-after-user-vote">has garnered sympathy from</a> right-wing personalities like Elon Musk and Tucker Carlson, confirmed the acquisition in a visibly distressed social media video, blaming &#8220;Democrats.&#8221;
Diamond Sports Group&#8216;s restructuring will include reducing its debt from nearly $9 billion to $200 million, <a href="https://www.espn.com/mlb/story/_/id/42388454/diamond-sports-group-emerges-bankruptcy">ESPN</a> reports. The restructuring plan received what Diamond categorized as &#8220;nearly unanimous support&#8221; from debt holders. Diamond, currently possessing $100 million in liquidity, will emerge from bankruptcy and operate as a stand-alone entity. Sinclair, the parent company, took on $8 billion in debt to buy regional channels from Fox for $10.6 billion in 2019. That debt contributed to Diamond&#8217;s bankruptcy.
<h3 class="wp-block-heading">Updates From The Block</h3>
Currently, there are no concrete indications that Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is actively pursuing a sale. Recent speculation regarding Humana being acquired by Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) was definitively addressed, with Cigna explicitly stating that it is <a href="https://www.benzinga.com/general/health-care/24/11/41877573/cigna-not-pursuing-humana-merger-stock-soars">not pursuing a merger</a> with Humana at this time. This clarification came after rumors reignited post-election, driven by the potential for more lenient antitrust reviews under the new <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">Republican administration and Congress</a>.
Spirit Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) is no longer in deal talks with Frontier Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>). It&#8217;s now in advanced discussions with bondholders to finalize a bankruptcy plan. The carrier continues to struggle with mounting losses and looming debt maturities. A bankruptcy filing is expected to happen within weeks, according to <a href="https://www.benzinga.com/news/earnings/24/11/41932146/spirit-airlines-nears-bankruptcy-creditors-may-approve-equity-cancellation-heres-what-it-means-for-investors-as-shares-fall-with-a-thud">the Wall Street Journal</a>.
MEI Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) continues to explore M&amp;A opportunities, hiring Oppenheimer &amp; Co., Inc. as an exclusive financial advisor to assist the process. During the first quarter of fiscal year 2025, the company commenced cash preservation efforts that include a reduction-in-force, which will continue in stages as the Company's operational and strategic direction evolves.
<h3 class="wp-block-heading">Notes From The Block</h3>
Wall Street anticipates a surge in M&amp;A as Republicans take control of Congress and deregulate. Analysts expect Federal Trade Commission Chair Lina Khan's removal, which could ease antitrust scrutiny. Bank of America highlights that Republican administrations, like President-elect Donald Trump&#8216;s, historically foster over 50% more financial sector M&amp;A activity compared to Democratic ones. 
Bank of America also predicts that 2025 could mark a better year for M&amp;A as rate cuts take effect and economic conditions stabilize. Here&#8217;s a list of five potential targets the bank compiled. For the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">full list, click here</a>.
<figure class="wp-block-table"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Market Cap ($M)</th>
<th>Free Cash Flows-to-Enterprise Value (%)</th>
<th>Long-Term Growth Expectations (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)</td>
<td>Health Care</td>
<td>13,932</td>
<td>4.4</td>
<td>25.3</td>
</tr>
<tr>
<td>Ralph LaurenCorp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)</td>
<td>Consumer Disc.</td>
<td>12,473</td>
<td>5.99</td>
<td>10.5</td>
</tr>
<tr>
<td>Paramount Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NYSE">PARA</a>)</td>
<td>Comm. Services</td>
<td>7,250</td>
<td>3.4</td>
<td>46.4</td>
</tr>
<tr>
<td>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>)</td>
<td>Technology</td>
<td>14,480</td>
<td>6.39</td>
<td>12.7</td>
</tr>
<tr>
<td>Hasbro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>)</td>
<td>Consumer Disc.</td>
<td>9,215</td>
<td>3.6</td>
<td>27.5</td>
</tr>
</tbody>
</table>
</figure>
For last week&#8217;s Deal Dispatch, <a href="https://www.benzinga.com/news/asset-sales/24/11/41866114/deal-dispatch-prison-companies-in-focus-post-election-tripadvisor-boasts-11b-in-cash">click here</a>.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41699259/nvidia-rides-ai-wave-to-replace-intel-on-dow-jones-industrial-average-ending-its-25-year-run">Nvidia Rides AI Wave To Replace Intel On Dow Jones Industrial Average, Ending Its 25-Year Run</a></li>
</ul>

Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul

Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $33 to $21.

Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $21

RBC Capital analyst Sean Dodge reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Outperform and maintains $20 price target.

RBC Capital Reiterates Outperform on Evolent Health, Maintains $20 Price Target

The latest announcement is out from Evolent Health ( ($EVH) ). Evolent Health announced its upcoming presentation at the 43rd Annual J.P. Morgan He...

Evolent Health to Present at J.P. Morgan Conference

Needham analyst Matthew Shea has reiterated their bullish stance on EVH stock, giving a Buy rating yesterday. Matthew Shea has given his Buy rating...

Evolent Health's Strategic Moves and Financial Outlook Garner Buy Rating from Analyst Matthew Shea

In an investor presentation for the 43rd Annual J.P. Morgan Healthcare Conference, Evolent Health (EVH) said it is reiterating its long-term outloo...

Evolent Health reiterates long-term outlook, says FY25 guide coming February 20

Truist analyst Jailendra Singh caught up with Evolent Health (EVH) post its presentation at an investor healthcare conference and also noted that t...

Evolent dips after Truist warns guidance may be 'significantly' below consensus

UBS analyst Kevin Caliendo lowered the firm's price target on Evolent Health (EVH) to $14 from $27 and keeps a Buy rating on the shares. The compan...

Evolent Health price target lowered to $14 from $27 at UBS

Truist lowered the firm's price target on Evolent Health (EVH) to $15 from $20 and keeps a Buy rating on the shares. The firm is updating its model...

Evolent Health price target lowered to $15 from $20 at Truist

Canaccord lowered the firm's price target on Evolent Health (EVH) to $16 from $23 and keeps a Buy rating on the shares. The firm looks at 2025 to b...

Evolent Health price target lowered to $16 from $23 at Canaccord

JMP Securities analyst Constantine Davides lowered the firm's price target on Evolent Health (EVH) to $12 from $18 and keeps an Outperform rating o...

Evolent Health price target lowered to $12 from $18 at JMP Securities

DOGE's Potential Impact - Top 10 IT And Software Companies With Exposure To The U.S. Government

TD Cowen lowered the firm's price target on Evolent Health (EVH) to $14 from $36 and keeps a Buy rating on the shares. The firm said they believe m...

Evolent Health price target lowered to $14 from $36 at TD Cowen

BBAI

CACI

DLHC

ICFI

IIIV

LDOS

PLTR

SAIC

Press Releases

Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.

Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify

Earnings

Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Evolent Announces Second Quarter 2024 Results

Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Define Ventures Appoints Bruce Broussard as Venture Partner

Evolent Announces Third Quarter 2024 Results

Humana and Evolent Expand Partnership to Enhance Oncology Care

Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025

HIMS

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OneMedNet

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

JP Morgan

Oppenheimer

Canaccord Genuity

Truist Securities

Stephens & Co.

<h3 class="wp-block-heading">새로이 등장한 블록</h3>
<ul>
<li>스타벅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 <a href="https://www.benzinga.com/news/asset-sales/24/11/42117962/starbucks-eyes-stake-sale-in-china-amid-fierce-competition-and-falling-sales">경제적 및 경쟁적 압박</a>에 적응하기 위한 파트너십을 모색하고 있다.</li>
</ul>
<h3 class="wp-block-heading">파산 블록</h3>
<ul>
<li>스낵 제조업체 하스사이드 푸드 솔루션스(Hearthside Food Solutions)이 파산했다. 사모펀드 소속 회사는 파트너스 그룹 홀딩 AG(Partners Group Holding AG)와 찰스뱅크 캐피털 파트너스(Charlesbank Capital Partners)의 소유 하에 쌓인 19억 달러의 부채를 정리하려고 한다. 두 회사는 하스사이드를 24억 달러 이상에 인수했다. 자산과 부채는 각각 10억 달러에서 100억 달러 사이이다. 작년에는 미국에서 파산한 사모펀드 포트폴리오 회사의 수가 <a href="https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/private-equity-portfolio-companies-on-track-for-most-bankruptcies-since-2020-74886821">2020년의 파산 건수를 초과</a>했다. 2024년이 더 나쁠지는 지켜봐야 한다.</li>
</ul>
<ul>
<li>노스볼트(Northvolt)가 58억 달러의 부채로 파산 신청을 했다. 스웨덴 배터리 제조업체인 노스볼트는 폭스바겐 AG(OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>)와 BMW AG(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMWYY#OTC">BMWYY</a>)에 배터리를 공급하며 작년에 <a href="https://www.benzinga.com/news/23/03/31506581/volkswagen-bmw-battery-supplier-northvolt-eyes-raising-5b-via-debt">부채를 조달하기 위해 은행과 협상</a>했던 기억이 있다. 이제는 미국 챕터 11 파산 보호 신청에 따라 구조조정을 희망하고 있다.</li>
</ul>
참고: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42024210/benzinga-bulls-and-bears-tesla-disney-gold-and-hedge-funds-project-bitcoin-to-hit-100k-150k">벤징가의 불스 및 베어스: 테슬라, 디즈니, 금 &#8211; 그리고 헤지펀드가 비트코인이 10만 달러에서 15만 달러에 이를 것이라고 전망</a>
<h3 class="wp-block-heading">블록에서의 업데이트</h3>
<ul>
<li>구글의 앤트로픽(Anthropic)에 대한 20억 달러 투자 계획이 <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">블룸버그</a>에 따르면 위험에 처해 있다. 앤트로픽은 제프 베이조스가 지원하는 인공지능(AI) 혁신 기업 오픈AI의 경쟁사입니다. 미국 법무부(DOJ)는 <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">수요일 법원 제출에서</a> 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)의 구글이 온라인 검색 독점을 해체하기 위해 크롬 브라우저를 매각해야 한다고 권고했다. 여기서 끝나지 않는다. 규제 당국은 구글이 소비자가 정보를 검색하는 곳을 제어하는 회사와 어떤 거래도 할 수 없도록 금지해야 한다고 말했다. <a href="https://www.benzinga.com/tech/24/11/42123646/google-anthropic-deal-in-jeopardy-as-us-justice-department-looks-to-snap-online-search-monopoly">이에는 AI 제품도 포함</a>된다.</li>
</ul>
<ul>
<li>리키 윌리엄스(Ricky Williams)의 하이즈맨(Highsman)이 대마초 브랜드 프로즌 필즈(Frozen Fields)와 합병하여 톱 시드(Top Seed Inc)를 형성했다. 이 파트너십은 대마초와 대마 산업 분야를 통합하여 제품을 <a href="https://www.benzinga.com/markets/cannabis/24/11/42097662/ricky-williams-highsman-merges-with-hemp-brand-frozen-fields">향상시키고 공급망을 통제</a>한다.</li>
</ul>
<ul>
<li>메이크마이트립(MakeMyTrip)이 하페이(Happay)를 크레드(CRED)로부터 인수했다. 이 거래는 인도에서 기업 여행 및 경비 관리 솔루션을 강화할 것으로 예상된다. 하페이의 팀은 메이크마이트립과 통합되어 <a href="https://www.benzinga.com/general/travel/24/11/42039458/makemytrip-agrees-to-acquire-happay-bolstering-its-arsenal-for-corporate-travel-solutions">900개 이상의 고객을 지원</a>할 것이다.</li>
</ul>
<ul>
<li>앰코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>)와 베리 글로벌 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>)가 주식 거래로 합병하기로 합의했으며, 이번 거래은 베리 주식을 주당 <a href="https://www.benzinga.com/news/large-cap/24/11/42069248/amcor-and-berry-seal-the-deal-73-59-per-share-merger-to-forge-packaging-powerhouse">73.59달러로 평가</a>했다.</li>
</ul>
<ul>
<li>일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NISTF#OTC">NISTF</a>)의 경영진이 펜실베니아로 출장을 가서 US 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 150억 달러 인수 제안을 지지받으려 했다. 이 일본 철강 거인은 워싱턴에서 정치적 저항에 직면하고 있다. 모리 타카히로(Takahiro Mori), 일본제철의 부회장이 인수 찬성을 위해 토요일에 피츠버그에 도착했다. 이 거래는 조 바이든 대통령과 도널드 트럼프 대통령 당선자가 모두 미국 철강회사가 <a href="https://www.benzinga.com/markets/24/11/42056111/nippon-steel-execs-rally-support-in-pennsylvania-amid-pushback-on-us-steel-takeover">미국 소유로 남아있기를 선호</a>한다고 반대에 직면하고 있다.</li>
</ul>
<h3 class="wp-block-heading">블록에서의 메모</h3>
다윈 파이낸셜 컴퍼니(Darwin Financial Company)의 공동 설립자 조슈아 로빈슨(Joshua Robinson)은 INYOAG LLC와의 5,500만 달러 자금 조달 거래를 발표했다. 이 자금은 캘리포니아 이노 카운티에 있는 태양열 발전 광산 개발에 사용될 예정이며, 해당 지역에는 은, 납, 아연, 텅스텐 및 구리 매장량이 확인되어 있다. 로빈슨과의 대화 내용은 다음과 같다:
<h4 class="wp-block-heading">BZ: 다윈 금융과 기초 금속 광산업체 INYOAG 간의 거래 구조는 어떻게 되나요? </h4>
로빈슨: 이번 거래 구조는 5,500만 달러 프로젝트 자금 조달 패키지로, 세 가지 구성 요소로 나누어진다: 황화물 및 산화물 생산에 각각 1,750만 달러 및 1,250만 달러의 6년 만기 채권, 그리고 광산이 월 1,000만 달러의 매출을 달성할 경우에만 발동되는 2,000만 달러의 조건부 주식 투자이다. 우리는 두 생산 트랙에서 총 매출의 17%를 확보하며, 이는 안전한 록박스 방식으로 구조화된다. 이것은 단순한 주식 투자가 아니며, 우리는 추가적인 상승 가능성을 제공하기 위해 특별히 이렇게 설계했다.
<h4 class="wp-block-heading">추가 투자자/합작 투자 파트너를 찾고 있나요? </h4>
네, 우리는 이것을 여러 층의 상승 가능성을 창출하기 위해 고의적으로 구조화했다. 이는 광산 분야에서 꽤 독특한 접근 방식이다. 우리는 생산에서의 단기 현금 흐름과 상당한 확장 가능성을 제공하는 하이브리드 모델을 만들었다. 우리는 이미 기존 광산 업체들로부터 관심을 받고 있지만, 특히 중요한 광물의 전략적 가치를 이해하는 새로운 투자자들을 이 분야에 끌어들이는 것에 대해 기대하고 있다.
<h4 class="wp-block-heading">중요 광물의 외국 공급원에 의존하는 것의 단점은 무엇인가요? </h4>
중국의 최근 움직임은 여기서 긴급성을 강조한다. 중국은 이미 게르마늄과 갈륨에 대한 수출 통제를 시행했고, 최근 안티모니도 목록에 추가했다. 이는 더 이상 이론적인 문제가 아니라, 실제로 발생하고 있다. 우리는 방산 및 기술에 필수적인 이러한 광물에 대해 공급망의 지역적 회복력을 구축해야 한다. 다윈 광산은 단일 자산에서 여러 중요한 광물의 국내 공급원을 구축할 수 있는 독특한 기회를 제공한다. 이는 찾기 어려운 일이다.
<h4 class="wp-block-heading">광산은 태양열로 운영되나요? </h4>
100MW 시설은 광산만을 전력 공급하는 것이 아니라, 우리가 생산하는 광물로 발전소 규모의 에너지 저장 시스템을 개발할 수 있는 충분한 청정 에너지를 생성할 것이다. 이는 우리의 광산 운영이 청정 에너지 배치를 직접 지원하는 선순환을 만든다.
<h4 class="wp-block-heading">2025년 목표는 무엇인가요? </h4>
2025년의 주요 목표는 자금 지원 후 6개월 이내에 황화물 생산을 하루 300톤으로, 9개월 이내에 산화물 생산을 하루 200톤으로 끌어올리는 것이다. 이는 월 1,000만 달러의 매출을 달성하게 되며, 그 후 심화된 광산 개발 프로그램이 발동다.
지난 주의 거래 소식은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%89%98-%EC%9C%A0%EB%8B%88%EB%A0%88%EB%B2%84-%EC%99%B8%EC%97%90%EB%8F%84-%EB%A7%A4%EA%B0%81-%EB%89%B4%EC%8A%A4-%EC%96%B4%EB%8B%88%EC%96%B8%EC%9D%B4/" target="_blank" rel="noopener">여기를 클릭하세요</a>.
지금 읽을 내용: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/ai-%EB%AC%BC%EA%B2%B0%EC%9D%84-%ED%83%80%EA%B3%A0-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EA%B0%80-%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-%EC%82%B0%EC%97%85%ED%8F%89%EA%B7%A0-%EC%A7%80%EC%88%98%EC%97%90/" target="_blank" rel="noopener">엔비디아, AI 붐으로 인텔을 다우존스 산업평균지수에서 교체하여 25년간의 지배를 종료</a></li>
</ul>
이미지: Benzinga
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

<h3 class="wp-block-heading">새로 등장한 블록</h3>
에볼런트 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/evh" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for EVH">EVH</a>)가 <a href="https://www.benzinga.com/m-a/24/08/40529349/evolent-health-explores-sale-garners-inbound-interest-from-private-equity-firms" target="_blank" rel="noopener" data-google-interstitial="false">매물로 나온 것</a>으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/tpg" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TPG">TPG</a>), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kkr" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KKR">KKR</a>)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/elv" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ELV">ELV</a>)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">암 치료제 개발에 주력하는 기업인 크로노스 바이오(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kron" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KRON">KRON</a>)가 인수나 합병 등 &#8216;전략적 대안&#8217;을 모색하고 있다. 캘리포니아주 샌머테이오에 본사를 둔 크로노스 바이오는 9월 30일 현재 1억 2,490만 달러의 현금 보유고를 보고했다.</div>
<div>
생고뱅(OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codgf" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODGF">CODGF</a>) (OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codyy" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODYY">CODYY</a>)은 <a href="https://www.bloomberg.com/news/articles/2024-11-13/st-gobain-is-said-to-weigh-2-5-billion-sale-of-auto-glass-unit" target="_blank" rel="noopener">블룸버그</a>에 따르면 최대 25억 유로(26억 달러)에 달하는 자동차 유리 사업부 매각을 고려하고 있다. 이 회사는 광범위한 비즈니스 평가의 일환으로 이러한 전략적 움직임을 고려하고 있는 것으로 알려졌다. 이번 매각은 운영을 간소화하고 핵심 사업 분야에 집중하려는 생고뱅(Saint-Gobain)의 노력과 일치한다.
쉘(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/shel" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SHEL" data-google-interstitial="false">SHEL</a>)은 탄소 상쇄 포트폴리오의 대부분을 <a href="https://www.bloomberg.com/news/articles/2024-11-13/shell-aims-to-sell-majority-stake-in-carbon-offsets-business?srnd=phx-deals" target="_blank" rel="noopener">폐기하려고</a> 한다. 이 회사는 <a href="https://www.bloomberg.com/news/features/2023-08-31/shell-silently-abandoned-its-100-million-a-year-plan-to-offset-co2-emissions" target="_blank" rel="noreferrer noopener">2018</a>년에 수십 개의 프로젝트를 포괄하는 오프셋 포트폴리오를 처음 출시했다.
</div>
유니레버(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)는 우녹스(Unox) 수프, 코니멕스(Conimex) 조미료 등 일부 네덜란드 식품 브랜드의 판매를 모색하고 있다. 로이터에 따르면 회사는 대신 자사의 가장 큰 &#8216;파워&#8217; 라벨에 집중할 것이라고 한다.
<h3 class="wp-block-heading">파산 블록</h3>
알렉스 존스(Alex Jones)의 미디어 회사인 인포워스(Infowars)가 디 어니언(The Onion)에 인수되었다는 소식이다. 이 거래의 뒷받침은 <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">샌디 훅(</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">Sandy Hook</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">) 피해자</a> 가족들로, 이들은 존스가 10억 달러 이상의 명예훼손 판결을 지고 있는 상황에서 이 거래를 시가에 상징적 정의라고 찬양했다. 일론 머스크 및 터커 칼슨 등 우파 인사들의 <a href="https://www.benzinga.com/news/23/12/36168941/elon-musks-controversial-move-alex-jones-returns-to-x-after-user-vote" target="_blank" rel="noopener" data-google-interstitial="false">동정을 받아온</a> 존스는 눈에 띄게 괴로워하는 소셜 미디어 영상을 통해 &#8220;민주당&#8221;을 비난하며 인수를 확인했다.
다이아몬드 스포츠 그룹(Diamond Sports Group)의 구조 조정에는 부채를 약 90억 달러에서 2억 달러로 줄이는 것이 포함될 것이라고 <a href="https://www.espn.com/mlb/story/_/id/42388454/diamond-sports-group-emerges-bankruptcy" target="_blank" rel="noopener">ESPN</a>이 보도했다. 구조조정 계획은 다이아몬드가 부채 보유자들로부터 &#8220;거의 만장일치의 지지&#8221;로 분류한 것을 받았다. 현재 1억 달러의 유동성을 보유하고 있는 다이아몬드는 파산 상태에서 벗어나 독립 기업으로 운영될 예정이다. 모회사인 싱클레어(Sinclair)는 2019년에 폭스(Fox)로부터 지역 채널을 106억 달러에 인수하기 위해 80억 달러의 빚을 졌다. 그 빚은 다이아몬드의 파산에 기여했다.
<h3 class="wp-block-heading">블록의 업데이트</h3>
현재 휴마나(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/hum" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HUM" data-google-interstitial="false">HUM</a>)가 적극적으로 매각을 추진하고 있다는 구체적인 징후는 없다. 시그나 그룹(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ci" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CI" data-google-interstitial="false">CI</a>)이 휴마나를 인수한다는 최근 추측이 확실하게 해결되었으며, 시그나는 현재로서는 휴마나와의 <a href="https://www.benzinga.com/general/health-care/24/11/41877573/cigna-not-pursuing-humana-merger-stock-soars" target="_blank" rel="noopener" data-google-interstitial="false">합병을 추진하지 않는다</a>고 명시적으로 밝혔다. 이러한 해명은 새로운 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">공화당 행정부와 의회</a> 하에서 보다 관대한 독점 금지 검토가 이루어질 가능성에 따라 선거 후 소문이 다시 불붙은 후에 나온 것이다.
스피릿 항공(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/save" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SAVE" data-google-interstitial="false">SAVE</a>)는 더 이상 프론티어 항공(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ulcc" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ULCC" data-google-interstitial="false">ULCC</a>)과 거래 협상을 진행하지 않는다. 현재 파산 계획을 확정하기 위해 채권 보유자와 사전 논의가 진행 중이다. 이 항공사는 계속해서 증가하는 손실과 다가오는 부채 만기 문제로 어려움을 겪고 있다. <a href="https://www.benzinga.com/news/earnings/24/11/41932146/spirit-airlines-nears-bankruptcy-creditors-may-approve-equity-cancellation-heres-what-it-means-for-investors-as-shares-fall-with-a-thud" target="_blank" rel="noopener" data-google-interstitial="false">월스트리트 저널</a>에 따르면 파산 신청은 몇 주 안에 이뤄질 것으로 예상된다.
<div class="ticker-wrapper">
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">
메이 파마(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/meip" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for MEIP" data-google-interstitial="false">MEIP</a>)는 계속해서 M&amp;A 기회를 모색하고 있으며 오펜하이머(Oppenheimer &amp; Co., Inc.)를 전담 재무 자문사로 고용하여 프로세스를 지원한다. 2025회계연도 1분기 동안 회사는 인력 감축을 포함한 현금 보존 노력을 시작했으며, 이는 회사의 운영 및 전략 방향이 발전함에 따라 단계적으로 계속될 것이다.
<h3 class="wp-block-heading">블록에서의 메모</h3>
월스트리트는 공화당이 의회를 장악하고 규제를 완화함에 따라 M&amp;A가 급증할 것으로 예상하고 있다. 분석가들은 리나 칸(Lina Khan) 연방거래위원회(FTC) 위원장의 해임으로 인해 독점 금지 조사가 쉬워질 것으로 예상하고 있다. 뱅크 오브 아메리카는 도널드 트럼프 대통령 당선자와 같은 공화당 행정부가 역사적으로 민주당 행정부에 비해 금융 부문 M&amp;A 활동을 50% 이상 육성했다는 점을 강조한다.
뱅크 오브 아메리카는 또한 금리 인하가 발효되고 경제 상황이 안정화됨에 따라 2025년은 M&amp;A에 있어 더 좋은 해가 될 수 있다고 예측한다. 다음은 은행이 수집한 5가지 잠재적 목표 목록이다. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">전체 목록</a>을 보려면 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">여기를 클릭</a>하세요.
<table class="block core-block table" style="height: 336px;" width="895">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>시가 총액 ($M)</th>
<th>기업 가치 대비 잉여 현금 흐름 (%)</th>
<th>장기 성장 기대치 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>유니버셜 헬스 서비스 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/uhs" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for UHS" data-google-interstitial="false">UHS</a>)</td>
<td>헬스케어</td>
<td>13,932</td>
<td>4.4</td>
<td>25.3</td>
</tr>
<tr>
<td>랄프 로렌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/rl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for RL" data-google-interstitial="false">RL</a>)</td>
<td>소비재</td>
<td>12,473</td>
<td>5.99</td>
<td>10.5</td>
</tr>
<tr>
<td>파라마운트 글로벌 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/para" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for PARA" data-google-interstitial="false">PARA</a>)</td>
<td>통신 서비스</td>
<td>7,250</td>
<td>3.4</td>
<td>46.4</td>
</tr>
<tr>
<td>자빌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jbl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JBL" data-google-interstitial="false">JBL</a>)</td>
<td>기술</td>
<td>14,480</td>
<td>6.39</td>
<td>12.7</td>
</tr>
<tr>
<td>해즈브로 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/has" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HAS" data-google-interstitial="false">HAS</a>)</td>
<td>소비재</td>
<td>9,215</td>
<td>3.6</td>
<td>27.5</td>
</tr>
</tbody>
</table>
</div>
</div>
지난주 딜 디스패치를 ​​보려면 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%84%A0%EA%B1%B0-%EC%9D%B4%ED%9B%84-%EA%B5%90%EB%8F%84%EC%86%8C-%ED%9A%8C%EC%82%AC%EB%93%A4%EC%97%90-%EC%B4%88%EC%A0%90-%ED%8A%B8%EB%A6%BD%EC%96%B4/" target="_blank" rel="noopener">여기를 클릭</a>하세요.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개의 중형주는 8월에 가장 좋은 성과를 보였다. 이 주식들이 귀하의 포트폴리오에 포함되어 있나요?
1. 폴스타 오토모티브 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>)의 주식이 8월에 74.19% 급등했다. 이는 <a href="https://www.benzinga.com//node/40629765" target="_blank" rel="noreferrer noopener">2분기 강력한 인도량</a>을 발표한 후 발생한 일이다.
2. 업스타트 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)의 주식이 67.32% 급등했다. 이는 회사가 <a href="https://www.benzinga.com//node/40322490" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>을 발표한 후 발생한 일이다.
3. 루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)의 주식이 58.13% 상승했다. 이는 <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener">엇갈린 2분기 실적</a>을 발표한 후 발생한 일이다.
4. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식이 52.46% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">컨센서스보다 좋은 2분기 주당 손실</a>을 발표한 후 발생한 일다.
5. 템푸스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>)의 주식이 51.17% 상승했다. 이는 주식이 구글과 <a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener">소프트뱅크 그룹</a>(OTCPK: SFTBF)의 투자로 인해 상승했다.
6. 클리어 시큐어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>)의 주식이 46.81% 상승했다. 이는 <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener">예상보다 좋은 분기 실적</a>을 발표한 후 발생한 일이다.
7. 아이오반스 바이오테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>)의 주식이 42.89% 상승했다. 이 회사는 2024년과 2025년을 위한 긍정적인 가이던스를 발표하고 <a href="https://www.benzinga.com//node/40288203" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>을 발표했다.
8. 에볼런트 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>)의 주식이 42.51% 상승했다. 이 회사는 <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">사모펀드와 의료 제공업체들</a>로부터 인수 문의를 받은 후 경매 절차를 시작했다.
9. 셈테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>)의 주식이 42.23% 상승했다. 이는 이 회사가 <a href="https://www.benzinga.com//node/40587744" target="_blank" rel="noreferrer noopener">2분기 실적을 초과 달성</a>했다고 발표한 후 발생한 일이다.
10. AST 스페이스모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)의 주식이 42.07% 상승했다. 이 회사는 <a href="https://www.benzinga.com//node/40398813" target="_blank" rel="noreferrer noopener">9월 초에 5개의 위성을 발사할 예정</a>이라고 발표했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%ea%b7%b8%eb%a6%ac%ea%b3%a0-%ec%8a%a4%ed%83%80%eb%b2%85%ec%8a%a4%eb%8a%94-8%ec%9b%94-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">어펌, 쇼피파이 그리고 스타벅스는 8월 최고 성과를 보여준 10개 대형주 중 일부</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9d%b8%ed%85%94-%eb%aa%a8%eb%8d%94%eb%82%98-%ea%b7%b8%eb%a6%ac%ea%b3%a0-%eb%8b%ac%eb%9f%ac-%ec%a0%9c%eb%84%88%eb%9f%b4%ec%9d%80-8%ec%9b%94-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc/" target="_blank" rel="noopener">인텔, 모더나 그리고 달러 제너럴은 8월 최악의 성과를 보인 10개 대형주 중 일부</a></li>
</ul>
사진 출처: 회사
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
1. 루시드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">캐나다의 다양한 금융 옵션</a>에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)가 <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 재무 결과</a>를 보고한 후 주가는 32.04% 상승했다.
3. 프로셉트 바이오로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>)가 <a href="https://www.benzinga.com/pressreleases/24/08/g40481411/procept-biorobotics-announces-fda-clearance-of-the-hydros-robotic-system-the-next-generation-ai-po" target="_blank" rel="noopener">자사의 하이드로스 로보틱(HYDROS Robotic) 시스템</a>에 대한 FDA 510(k) 승인을 발표한 후 주가는 22.67% 상승했다.
4. 크레도 테크놀로지 그룹 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)의 주식이 20.02% 상승했다.
5. 에볼런트 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>)가 <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매각을 모색하고</a> 있다는 보고서가 나온 후 주가는 19.98% 상승했다.
6. 그리폴스 S.A.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) 주식이 19.50% 급등했다. 이는 브룩필드 에셋 매니지먼트(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/bam" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BAM" data-google-interstitial="false">BAM</a>)가 회사를 인수하기 위해 부채 자금을 모색하고 있다는 보도가 나온 후 발생한 일이다.
7. 뉴발런트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>)의 주식이 19.33% 상승했다.
8. 에이머 스포츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>)가 예상보다 나은 2분기 <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">실적을 보고하고 FY24 EPS 전망을 상향</a> 조정한 후 주식이 16.60% 급등했다.
추가로 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%a4%8c-%eb%b9%84%eb%94%94%ec%98%a4-%eb%b0%8f-%ed%83%80%ea%b9%83%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-11%ea%b0%9c-%eb%8c%80/" target="_blank" rel="noopener">줌 비디오 및 타깃은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%8a%a4%eb%85%b8%ec%9a%b0%ed%94%8c%eb%a0%88%ec%9d%b4%ed%81%ac-%eb%b0%8f-jd%eb%8b%b7%ec%bb%b4-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-8/" target="_blank" rel="noopener">스노우플레이크 및 JD닷컴 지난주 최악의 성과를 보인 8개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Evolent Health

뉴스

에 대한 최신 뉴스 Evolent Health (NYSE:EVH) 주식

토요일, 11월 23, 2024

일요일, 11월 17, 2024

일요일, 9월 08, 2024

일요일, 8월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌